Here, we show that DFMO treatment of ovarian tumor cell lines resulted in increased cisplatin-mediated cytotoxicity in HR-competent cells when combined with the widely used PARP inhibitor, rucaparib. The gene discussed is PARP1; the disease is ovarian neoplasm.